Robert Bloom
Hematology & Oncology · Southfield, MINPI 1760413389
Payments from drug & device makers
Across 79 payments — averaging $90.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Agios Pharmaceuticals, Inc.$5K
- GSK$825
- Beigene USA, Inc.$525
- E.r. Squibb & Sons, L.L.C.$250
- Genentech USA, Inc.$180
- Gilead$156
- plus $724 from 20 others
What the payments were for
- Consulting fees$4,15058%
- Travel & lodging$1,26418%
- Food & beverage$1,75925%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 13 | $4,514 |
| GSK | 1 | $825 |
| Beigene USA, Inc. | 1 | $525 |
| E.r. Squibb & Sons, L.L.C. | 14 | $250 |
| Genentech USA, Inc. | 7 | $180 |
| Gilead(2 entities) | 3 | $156 |
| Seagen Inc. | 1 | $108 |
| AstraZeneca(2 entities) | 5 | $75 |
| Merck | 5 | $75 |
| Johnson & Johnson | 3 | $67 |
| Amgen | 4 | $57 |
| Novartis | 3 | $42 |
| Bayer | 2 | $35 |
| AbbVie | 2 | $33 |
| Dynavax Technologies Corporation | 2 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| EMD Serono, Inc. | 2 | $22 |
| Bristol Myers Squibb | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Clovis Oncology, Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $16 |
| Vyera Pharmaceuticals, LLC | 1 | $15 |
| Pfizer | 1 | $13 |
| Tersera Therapeutics LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,173 in reported general payments places this provider in the 60th percentile of 282 hematology & oncology providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SprycelDasatinib | 11 | $179,434 |
| Ondansetron OdtOndansetron | 13 | $949 |
| Anastrozole | 33 | $765 |
| Hydroxyurea | 21 | $748 |
| Morphine Sulfate ErMorphine Sulfate | 14 | $631 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $354 |
| Morphine Sulfate | 13 | $235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Sprycel | $250 | $179,43411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Southfield
- Andrew MuskovitzSouthfield$61K
- Sreenivasa ChandanaGrand Rapids$19.1M
- Nehal LakhaniGrand Rapids$15M
- Hirva MamdaniDetroit$9.5M
- Jeffrey ZonderDetroit$8.2M
- Assuntina SaccoAnn Arbor$8.1M
- Abhinav DeolDetroit$4.5M
- Harsh ShahDetroit$2.6M
- Igor RybkinDetroit$2.4M
- Jason BrownAnn Arbor$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.